|Bid||633.00 x 0|
|Ask||633.50 x 0|
|Day's range||632.50 - 645.24|
|52-week range||554.00 - 891.79|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||28.36|
|Earnings date||16 Sept 2021|
|Forward dividend & yield||0.08 (1.21%)|
|Ex-dividend date||02 Dec 2021|
|1y target est||774.55|
BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Clinigen Group plc...